The latest price target for TransCode Therapeutics (NASDAQ:RNAZ) was reported by HC Wainwright & Co. on December 18, 2024. The analyst firm set a price target for $20.00 expecting RNAZ to rise to within 12 months (a possible 422.19% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for TransCode Therapeutics (NASDAQ:RNAZ) was provided by HC Wainwright & Co., and TransCode Therapeutics maintained their buy rating.

There is no last upgrade for TransCode Therapeutics

There is no last downgrade for TransCode Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TransCode Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TransCode Therapeutics was filed on December 18, 2024 so you should expect the next rating to be made available sometime around December 18, 2025.

While ratings are subjective and will change, the latest TransCode Therapeutics (RNAZ) rating was a maintained with a price target of $3.00 to $20.00. The current price TransCode Therapeutics (RNAZ) is trading at is $3.83, which is within the analyst’s predicted range.